



Ageing with HIV conference



"young by age – old by treatment"





Day 2: Testing in children and adolescents

"we'll pay the price later"

Observations

Low testing is happening in < 25y people but prevalence and incidence are increasing in young population

High percentage recognised as vulnerable population

- ⇒ Upscaling testing is needed < 18 year old people
- ⇒ Better information and mobilization (and normalization of testing)
- ⇒ Make testing possible without guardian's permission





Day 2: Disclosure: how and when?

"no bugs, no battles, no war"

Observations

Disclosure often happens rather late and this has impact on future (mental) health and relationships

Chosing the right moment is important

- ⇒ Don't dramatize HIV (but disclosure remains difficult)
- ⇒ Work on stigma and discrimination (also from direct surrounding)
- ⇒ Positive messaging





Day 2: Paediatric ARV formulations

"children are different so there is a need to tailor treatment"

Observations

Better access to treatment but suboptimal treatments are still being used. Earlier treatment should be possible.

Most variabilities below 6 years (but understudied group)

- ⇒ More research within children/very young children
- ⇒ Support adherence and improve retention to care
- ⇒ Simplify paediatric treatments (and create new and better options)





Day 2:Pharmacology of ARVs

"take control - doctors make mistakes"

Observations

Impact of puberty, genetics and metabolism

- ⇒ More research needed and improved paediatric options
- ⇒ Underuse of pharmacogenetics in treatment
- ⇒ Better understanding needed of infancy, childhood and puberty
- ⇒ Listen and support good doctor/patient relationship